FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2793085333> ?p ?o ?g. }

• W2793085333 abstract "BACKGROUND Pain is the hallmark of sickle cell disease (SCD) and it can be severe, frequent and unpredictable. Although nociceptive pain is more common, at times, people with SCD may have neuropathic pain. The latter can occur due to peripheral or central nerve injury. This review is focused on identifying treatment of only painful sensory neuropathy in people with SCD. OBJECTIVES To determine the effectiveness and safety of any pharmacological or non-pharmacological therapies for treating neuropathic pain in people with SCD. SEARCH METHODS We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books. We also searched trial registries, the reference lists of relevant articles and reviews and contacted experts in the field.Date of last search: 31 January 2019. SELECTION CRITERIA Randomised controlled trials (RCTs) (parallel or cross-over in design), quasi-RCTs of pharmacological or non-pharmacological therapies for treating neuropathic pain in people with SCD compared to placebo or another intervention in any category (i.e. pharmacological or non-pharmacological). DATA COLLECTION AND ANALYSIS Two review authors independently assessed all trials identified by the searches and extracted relevant data. Two authors independently assessed the risk of bias in the selected trials using the Cochrane risk of bias tool. Two review authors independently rated the quality of the evidence for each outcome using the GRADE guidelines. MAIN RESULTS One RCT of 22 participants with SCD, conducted in the USA was included in this review. Participants were randomly assigned to either pregabalin (n = 11) or placebo (n = 11). Oral pregabalin was administered at an initial dose of 75 mg twice daily. The drug was titrated at increments of 75 mg to a maximum of 600 mg daily or decreased by 75 mg per day if necessary, based on clinical presentation and pain level. Neuropathic pain was assessed using self-reports on the Leeds Assessment of Neuropathic Symptoms and Signs (S-LANNS) scale and the Neuropathic Pain Symptom Inventory (NPSI), where higher scores were indicative of more pain. Outcomes included self-reported pain, quality of life and withdrawal due to adverse effects measured at baseline and monthly for three months post-intervention. The overall risk of bias was low with a high risk of bias due to attrition.In relation to this reviews primary outcomes, for self-reported neuropathic pain relief, given the paucity of data, we are very uncertain whether there is a difference between the pregabalin and placebo groups at the end of three months as measured by the S-LANSS scale, mean difference (MD) -2.00 (95% confidence interval (CI) -9.18 to 5.18), or the NPSI scale, MD -11.10 (95% CI -33.97 to 11.77) (very low-quality evidence). There was no report of 'Patient Global Impression of Change' in the included trial.Although the mean quality of life scores (Short Form-36) at three months showed small increases in seven of the eight domains post-intervention in the pregabalin group as compared to the placebo group, this was very low-quality evidence and we are very uncertain whether pregabalin increases quality of life. Neither of our pre-defined outcomes of 'time to improvement of symptoms' or 'changes in sleep quality', were measured in the included trial.While treatment-related adverse effects appeared higher in pregabalin group than the placebo group at three months, this was very low-quality evidence and we are very uncertain whether there is a difference, RR 1.33 (95% CI 0.39 to 4.62) (very low-quality evidence). There was one withdrawal for adverse effects in the pregabalin group while three people withdrew or dropped out from the placebo group due to adverse effects and complications and hospitalisation related to SCD. AUTHORS' CONCLUSIONS The included trial provided very low-quality evidence. Self-reported pain relief was greater in the pregabalin group compared to the placebo control group but only using the S-LANSS scale and we are very unsure whether there is a difference. While the pregabalin group tended to have improved quality of life over the duration of the trial, this was very low-quality evidence and we are uncertain whether there is a difference. Adverse effects and withdrawals were similar across the treatment and placebo control group in trial. There are both insufficient trials addressing this review question and insufficient outcomes addressed in the single included RCT. Therefore, there is still a significant gap in evidence on interventions for neuropathic pain in people with SCD." @default.
• W2793085333 created "2018-03-29" @default.
• W2793085333 creator A5030645825 @default.
• W2793085333 creator A5033734393 @default.
• W2793085333 creator A5042923202 @default.
• W2793085333 creator A5067632920 @default.
• W2793085333 creator A5079314051 @default.
• W2793085333 date "2018-02-05" @default.
• W2793085333 modified "2023-09-27" @default.
• W2793085333 title "Interventions for treating neuropathic pain in people with sickle cell disease" @default.
• W2793085333 cites W1582187353 @default.
• W2793085333 cites W1959946539 @default.
• W2793085333 cites W1964065290 @default.
• W2793085333 cites W1984530537 @default.
• W2793085333 cites W1989851079 @default.
• W2793085333 cites W1996724062 @default.
• W2793085333 cites W2018519248 @default.
• W2793085333 cites W2027662398 @default.
• W2793085333 cites W2040381945 @default.
• W2793085333 cites W2042741271 @default.
• W2793085333 cites W2045091873 @default.
• W2793085333 cites W2045552353 @default.
• W2793085333 cites W2053495832 @default.
• W2793085333 cites W2074901521 @default.
• W2793085333 cites W2079711079 @default.
• W2793085333 cites W2080996329 @default.
• W2793085333 cites W2096602019 @default.
• W2793085333 cites W2097744101 @default.
• W2793085333 cites W2104818454 @default.
• W2793085333 cites W2115657655 @default.
• W2793085333 cites W2119617723 @default.
• W2793085333 cites W2124240321 @default.
• W2793085333 cites W2125435699 @default.
• W2793085333 cites W2134097317 @default.
• W2793085333 cites W2145981101 @default.
• W2793085333 cites W2153913352 @default.
• W2793085333 cites W2161344815 @default.
• W2793085333 cites W2163777897 @default.
• W2793085333 cites W2588413211 @default.
• W2793085333 cites W2607346125 @default.
• W2793085333 cites W2914437448 @default.
• W2793085333 cites W40076414 @default.
• W2793085333 cites W4211186710 @default.
• W2793085333 cites W4256526181 @default.
• W2793085333 cites W4256532909 @default.
• W2793085333 cites W4294215472 @default.
• W2793085333 doi "https://doi.org/10.1002/14651858.cd012943" @default.
• W2793085333 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6609827" @default.
• W2793085333 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31273755" @default.
• W2793085333 hasPublicationYear "2018" @default.
• W2793085333 type Work @default.
• W2793085333 sameAs 2793085333 @default.
• W2793085333 citedByCount "4" @default.
• W2793085333 countsByYear W27930853332020 @default.
• W2793085333 countsByYear W27930853332021 @default.
• W2793085333 countsByYear W27930853332022 @default.
• W2793085333 crossrefType "journal-article" @default.
• W2793085333 hasAuthorship W2793085333A5030645825 @default.
• W2793085333 hasAuthorship W2793085333A5033734393 @default.
• W2793085333 hasAuthorship W2793085333A5042923202 @default.
• W2793085333 hasAuthorship W2793085333A5067632920 @default.
• W2793085333 hasAuthorship W2793085333A5079314051 @default.
• W2793085333 hasBestOaLocation W27930853332 @default.
• W2793085333 hasConcept C118552586 @default.
• W2793085333 hasConcept C126322002 @default.
• W2793085333 hasConcept C142724271 @default.
• W2793085333 hasConcept C168563851 @default.
• W2793085333 hasConcept C17744445 @default.
• W2793085333 hasConcept C1862650 @default.
• W2793085333 hasConcept C189708586 @default.
• W2793085333 hasConcept C199539241 @default.
• W2793085333 hasConcept C204787440 @default.
• W2793085333 hasConcept C27081682 @default.
• W2793085333 hasConcept C27415008 @default.
• W2793085333 hasConcept C2777107010 @default.
• W2793085333 hasConcept C2779134260 @default.
• W2793085333 hasConcept C2779473830 @default.
• W2793085333 hasConcept C2780665704 @default.
• W2793085333 hasConcept C2781118164 @default.
• W2793085333 hasConcept C42219234 @default.
• W2793085333 hasConcept C535046627 @default.
• W2793085333 hasConcept C71924100 @default.
• W2793085333 hasConceptScore W2793085333C118552586 @default.
• W2793085333 hasConceptScore W2793085333C126322002 @default.
• W2793085333 hasConceptScore W2793085333C142724271 @default.
• W2793085333 hasConceptScore W2793085333C168563851 @default.
• W2793085333 hasConceptScore W2793085333C17744445 @default.
• W2793085333 hasConceptScore W2793085333C1862650 @default.
• W2793085333 hasConceptScore W2793085333C189708586 @default.
• W2793085333 hasConceptScore W2793085333C199539241 @default.
• W2793085333 hasConceptScore W2793085333C204787440 @default.
• W2793085333 hasConceptScore W2793085333C27081682 @default.
• W2793085333 hasConceptScore W2793085333C27415008 @default.
• W2793085333 hasConceptScore W2793085333C2777107010 @default.
• W2793085333 hasConceptScore W2793085333C2779134260 @default.
• W2793085333 hasConceptScore W2793085333C2779473830 @default.
• W2793085333 hasConceptScore W2793085333C2780665704 @default.
• W2793085333 hasConceptScore W2793085333C2781118164 @default.
• W2793085333 hasConceptScore W2793085333C42219234 @default.
• W2793085333 hasConceptScore W2793085333C535046627 @default.

• next